Navigation Links
Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
Date:12/12/2012

SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that it has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics, Inc., or Incline.

Under the waiver, consent and option termination agreement signed by Cadence and Incline, upon the closing of the proposed acquisition of Incline by The Medicines Company (Nasdaq: MDCO), Cadence would receive a payment of approximately $13 million to buy-out Cadence's interest in, and terminate Cadence's rights with respect to, the option agreement. Additionally, Cadence would receive approximately $1.5 million related to the purchase by The Medicines Company of the shares of Incline common stock held by Cadence, subject to adjustment, and, potentially, a pro rata share of future milestone payments. The acquisition of Incline by The Medicines Company is subject to the satisfaction or waiver of customary closing conditions, and is currently expected to close in January, 2013.

"The sale of our Incline option provides Cadence with non-dilutive capital and a solid return on our original investment," said Ted Schroeder, President and CEO of Cadence. "We're excited about the continued growth in sales of OFIRMEV, and believe that today's announcement provides us with further flexibility to focus on other drivers of near term revenue growth."

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding the anticipated closing date for the acquisition of Incline by The Medicines Company, the potential for Cadence to receive payments related to that transaction, and the potential for continued growth in sales of OFIRMEV, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: the risk that the closing of the Incline acquisition may be delayed or may not occur at all; and Cadence's dependence on the successful commercialization of OFIRMEV, which is Cadence's only product; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the SEC from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and the company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc. Contact:

 William R. LaRue

Kelli France SVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals to Host Analyst and Investor Day
2. Cadence to Open Finished Medical Device Facility
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
4. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
7. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
9. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
10. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
11. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... Virginia (PRWEB) , ... September 21, 2017 , ... ... health in their communities, nine governmental public health departments have been awarded five-year ... accreditation decisions mean that the benefits of being served by a PHAB-accredited ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
Breaking Medicine News(10 mins):